Anne-lise Bienvenu

Neuroprotection and Cerebral Malaria: a New Paradigm for Treatment Anne-lise Bienvenu

There are at least 300 million cases of malaria each year, resulting in more than a million deaths. Cerebral malaria is the most severe complication of malaria especially in young African children. Besides drug resistance, another challenge in the fight against malaria is the protective treatment of the host combined to the conventional antimalarial treatment. This opportunity came with the consideration of cerebral malaria residual case fatality rate of about 20%, despite a timely adequate antimalarial treatment. This work describes the available experimental model of cerebral malaria, the place of neuroprotective therapies in this disease and the efficacy of two neuroprotective drugs, recombinant erythropoietin and statins, during experimental cerebral malaria. Last, a proof- of-concept study documented the relevance of neuroprotection during human cerebral malaria in endemic area. This work should give new insights in medical practices. It should be especially useful to clinicians involved in critical care, infectious diseases, or neurological diseases.